Literature DB >> 11714197

Cartilage produced after transplantation of syngeneic chondrocytes is rejected in rats presensitized with allogeneic chondrocytes.

S Moskalewski1, A Osiecka-Iwan, A Hyc.   

Abstract

Cartilage produced in 2-week-old intramuscular transplants of syngeneic chondrocytes in rats did not display any signs of rejection. Cartilage produced by similar transplants in animals presensitized with intramuscular transplants of allogeneic chondrocytes was surrounded by infiltrations composed mainly of lymphocytes and was partially resorbed. Spleen mononuclear cells (SMC) from recipients of syngeneic transplants alone were not stimulated in mixed splenocyte-chondrocyte cultures by syngeneic or allogeneic chondrocytes. SMC from recipients of allogeneic and subsequent syngeneic transplants were strongly stimulated by both syngeneic and allogeneic chondrocytes, although stimulation by the latter was significantly more pronounced. Sera from naive rats usually contained cytotoxic antichondrocyte antibodies but their level varied considerably in various individuals. In rats chosen as transplant recipients on the basis of low antichondrocyte cytotoxicity of their sera, this toxicity was markedly raised after sensitization with allo- and syngeneic chondrocytes. Absorption with thymocytes or fibroblasts decreased but did not abrogate cytotoxicity. These observations support previous reports suggesting expression of tissue-specific antigen(s) by chondrocytes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11714197

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  2 in total

1.  Cytotoxic T lymphocytes recognize and lyse chondrocytes under inflammatory, but not non-inflammatory conditions.

Authors:  E Suzanne Cohen; Helen C Bodmer
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

Review 2.  Antigenic and immunogenic properties of chondrocytes. Implications for chondrocyte therapeutic transplantation and pathogenesis of inflammatory and degenerative joint diseases.

Authors:  Anna Osiecka-Iwan; Anna Hyc; Dorota M Radomska-Lesniewska; Adrian Rymarczyk; Piotr Skopinski
Journal:  Cent Eur J Immunol       Date:  2018-06-30       Impact factor: 2.085

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.